Eli Lilly and Company
Tažením v grafu vyberte úsek a zobrazí se procentuální změna.Tažením dvěma prsty vyberte úsek a zobrazí se procentuální změna.
Kapitálová struktura
- Tržní kapitalizace
- 1,05 bil. US$
- Enterprise Value
- 1,1 bil. US$
- Hotovost
- 8,95 mld. US$
- Celkový dluh
- 54,91 mld. US$
- Čistý dluh
- 45,96 mld. US$
Valuace (TTM)
- P/E
- 39,59×
- P/E (fwd)
- 24,76×
- P/FCF
- 77,55×
- FCF výnos
- 1,29 %
- EV/EBITDA
- 26,31×
- P/S
- —
- P/B
- 31,03×
- Beta
- 0,45
Marže (TTM)
- Hrubá marže
- 83,40 %
- EBITDA marže
- 52,35 %
- Provozní marže
- 54,22 %
- Čistá marže
- 33,53 %
- FCF marže
- 17,02 %
Ziskovost a růst
- ROE (rentabilita kapitálu)
- 102,29 %
- Růst tržeb (YoY)
- 47,70 %
- Růst zisku (YoY)
- 26,20 %
Dividenda
- Dividendový výnos
- 0,59 %
- Roční dividenda
- 6,92 US$
- Výplatní poměr
- 21,69 %
- Datum ex-dividendy
- 2026-08-14
52týdenní rozpětí
- Aktuální
- 1 179,27 US$
- Pozice v pásmu
- 78 %
- Nad ročním minimem
- +50,45 %
- Pod ročním maximem
- -8,77 %
Cena v kontextu
- Historické maximum
- 1 280,34 US$
- Datum maxima
- 19. 8. 2026
- Zpět na maximum
- +8,57 %
- 200denní průměr
- 1 075,99 US$
- Odchylka od průměru
- +9,60 %
O společnosti
WebEli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Vedení společnosti
- Mr. Lucas E. MontarceExecutive VP & CFO
- Dr. Daniel M. Skovronsky M.D., Ph.D.Chief Scientific & Product Officer and President of Lilly Research Laboratories
- Ms. Anat Hakim J.D.Executive VP, General Counsel & Secretary
- Mr. Jacob S. Van NaardenExecutive VP, President of Lilly Oncology & Head of Corporate Business Development
- Mr. Donald A. ZakrowskiSenior VP of Finance & Chief Accounting Officer
- Mr. Diogo RauExecutive VP and Chief Information & Digital Officer
- Mr. Michael CzaparSenior Vice President of Investor Relations
- Mr. Eric DozierExecutive VP & Chief People Officer
- Mr. Ilya YuffaExecutive VP and President of Lilly USA & Global Customer Capabilities